

Theralase Announces Breakthrough Scientific Research

For Immediate Release

Toronto, Ontario - October 7, 2008

Theralase® Technologies Inc. (TSX-V: TLT) today announced the completion of independent scientific research performed at University Health Network demonstrating that Theralase's® proprietary super-pulsed 905 nanometer (nm) laser technology produces significantly more nitric oxide as compared to other tested laser sources.

Nitric oxide production has been previously demonstrated in published clinical studies to increase the diameter of capillaries, bringing much needed oxygen and fuel molecules to injured tissue, accelerating their natural healing processes, as well as activating and controlling inflammation. The high effect of the Theralase® super-pulsed 905 nm laser technology has been scientifically demonstrated to be due to laser-tissue interactions which can not be attained by non-super-pulsed techniques.

"We are pleased to demonstrate what our customers have always known, that the Theralase® proprietary 905 nm super-pulsed technology has created the best therapeutic laser on the market," said Roger Dumoulin-White, President & CEO of Theralase® Technologies. "Our technology has been scientifically proven to activate both known cellular pathways: the ATP pathway, which increases the energy to cells, and the Nitric Oxide pathway, which increases the blood flow to cells, while also reducing inflammation. By activating both known cellular pathways, the Theralase® proprietary 905 nm super-pulsed technology has now been proven to be more effective in neural muscular skeletal conditions, wound healing and chronic pain as compared to competitive systems."

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors: firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions including arthritis; secondly, to bio-stimulate and accelerate wound care and healing including bone fracture regeneration; and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancer, bacteria, viruses and fat cells.

For further information, please contact:

Roger White, President & CEO
Toll Free: 1-866-THE-LASE (843-5273)
Phone: (416) 447-8455
e-mail: rwhite@theralase.com

Vanessa Beresford
The Equicom Group
Phone : (416) 815 0700 ext 227
e-mail: vberesford@equicomgroup.com

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.